|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
PT2454282E
(pt)
|
2009-07-13 |
2015-06-23 |
Zealand Pharma As |
Análogos de glucagão acilados
|
|
DK2462246T3
(da)
|
2009-09-28 |
2017-11-06 |
Intarcia Therapeutics Inc |
Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
|
|
JP6006118B2
(ja)
|
2009-12-16 |
2016-10-12 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アナログ及び誘導体
|
|
US9708383B2
(en)
*
|
2010-11-09 |
2017-07-18 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives
|
|
RU2600440C3
(ru)
|
2010-12-16 |
2021-12-10 |
Ново Нордиск А/С |
Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
|
|
US20120208755A1
(en)
*
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CA2832811A1
(en)
|
2011-04-12 |
2012-10-18 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
US9353172B2
(en)
|
2011-07-18 |
2016-05-31 |
Arts Biologics A/S |
Long acting biologically active luteinizing hormone (LH) compound
|
|
ES2626013T3
(es)
*
|
2011-09-06 |
2017-07-21 |
Novo Nordisk A/S |
Derivados de GLP-1
|
|
KR101922164B1
(ko)
|
2011-12-29 |
2019-02-13 |
노보 노르디스크 에이/에스 |
비-단백질원 아미노산을 포함하는 디펩티드
|
|
WO2013127779A1
(en)
|
2012-03-01 |
2013-09-06 |
Novo Nordisk A/S |
Glp-1 prodrugs
|
|
US10933120B2
(en)
|
2012-03-22 |
2021-03-02 |
Novo Nordisk A/S |
Compositions of GLP-1 peptides and preparation thereof
|
|
ES2715308T3
(es)
|
2012-03-22 |
2019-06-03 |
Novo Nordisk As |
Composiciones que comprenden un agente de suministro y su preparación
|
|
AR090937A1
(es)
|
2012-05-03 |
2014-12-17 |
Zealand Pharma As |
Compuestos agonista duales de gip-glp-1 y metodos para usarlos
|
|
WO2013167454A1
(en)
|
2012-05-08 |
2013-11-14 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
JP6366575B2
(ja)
*
|
2012-05-08 |
2018-08-01 |
ノヴォ ノルディスク アー／エス |
二重アシル化されたｇｌｐ−１誘導体
|
|
WO2013170636A1
(zh)
|
2012-05-18 |
2013-11-21 |
爱德迪安（北京）生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
|
ES2871328T3
(es)
|
2012-06-20 |
2021-10-28 |
Novo Nordisk As |
Formulación de comprimido que comprende un péptido y un agente de suministro
|
|
PL2866825T3
(pl)
|
2012-07-01 |
2021-02-22 |
Novo Nordisk A/S |
<div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div>
|
|
BR112015001451B1
(pt)
|
2012-07-23 |
2022-03-29 |
Zealand Pharma A/S |
Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável
|
|
FR2994848B1
(fr)
|
2012-08-30 |
2014-08-22 |
Univ Paris Curie |
Traitement de l'arthrose par les hormones incretines ou leurs analogues
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
WO2014067084A1
(zh)
*
|
2012-10-31 |
2014-05-08 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的制备方法
|
|
PT2934568T
(pt)
|
2012-12-21 |
2018-01-04 |
Sanofi Sa |
Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
|
|
AU2014261336B2
(en)
*
|
2013-05-02 |
2019-02-28 |
Novo Nordisk A/S |
Oral dosing of GLP-1 compounds
|
|
KR20160021183A
(ko)
*
|
2013-06-20 |
2016-02-24 |
노보 노르디스크 에이/에스 |
Glp-1 유도체 및 그것의 용도
|
|
US9498534B2
(en)
*
|
2013-07-04 |
2016-11-22 |
Novo Nordisk A/S |
Derivatives of GLP-1 like peptides, and uses thereof
|
|
CN105451776B
(zh)
|
2013-08-15 |
2020-04-17 |
诺和诺德股份有限公司 |
Glp-1衍生物及其用途
|
|
CN105792851B
(zh)
|
2013-09-13 |
2023-10-10 |
斯克利普斯研究所 |
修饰的治疗剂及其组合物
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
MX368436B
(es)
|
2013-10-17 |
2019-10-03 |
Zealand Pharma As |
Analogos de glucagon acilados.
|
|
CA2929459C
(en)
|
2013-11-06 |
2022-05-03 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
KR102310392B1
(ko)
|
2013-11-06 |
2021-10-13 |
질랜드 파마 에이/에스 |
글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
|
|
US10626156B2
(en)
|
2013-12-06 |
2020-04-21 |
Jie Han |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／ｇｉｐ受體促效劑
|
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／升糖素受體促效劑
|
|
AU2014364589B2
(en)
|
2013-12-18 |
2020-02-27 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
CN106132985B
(zh)
*
|
2014-04-07 |
2020-10-13 |
诺和诺德股份有限公司 |
双酰化glp-1化合物
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
KR101981532B1
(ko)
|
2014-06-12 |
2019-09-02 |
라 파마슈티컬스 인코포레이티드 |
보체 활성의 조절
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
ES2883345T3
(es)
|
2014-10-29 |
2021-12-07 |
Zealand Pharma As |
Compuestos agonistas del GIP y métodos
|
|
CN106999602B
(zh)
*
|
2014-11-27 |
2022-02-01 |
诺和诺德股份有限公司 |
Glp-1衍生物及其用途
|
|
JP6691125B2
(ja)
|
2014-12-17 |
2020-04-28 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体及びその使用
|
|
PL3250230T3
(pl)
|
2015-01-28 |
2022-02-14 |
Ra Pharmaceuticals, Inc. |
Modulatory aktywności dopełniacza
|
|
JP7211704B2
(ja)
*
|
2015-01-29 |
2023-01-24 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
|
|
CN107205949A
(zh)
*
|
2015-01-29 |
2017-09-26 |
诺和诺德股份有限公司 |
包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物
|
|
PL3283507T3
(pl)
|
2015-04-16 |
2020-05-18 |
Zealand Pharma A/S |
Acylowany analog glukagonu
|
|
US10925639B2
(en)
|
2015-06-03 |
2021-02-23 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
|
US10118904B2
(en)
|
2015-06-05 |
2018-11-06 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of Demyelinating Diseases
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
EP3319968A1
(en)
|
2015-07-06 |
2018-05-16 |
Rodin Therapeutics, Inc. |
Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
|
|
ES2899906T3
(es)
|
2015-07-06 |
2022-03-15 |
Alkermes Inc |
Inhibidores bicíclicos de histona desacetilasa
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|
|
CN106496322A
(zh)
*
|
2015-09-07 |
2017-03-15 |
江苏恒瑞医药股份有限公司 |
人胰岛素或其类似物的酰化衍生物的制备方法
|
|
CA3003465A1
(en)
*
|
2015-10-28 |
2017-05-04 |
Krishna Kumar |
Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
|
|
RU2733720C2
(ru)
|
2015-12-16 |
2020-10-06 |
Ра Фармасьютикалз, Инк. |
Модуляторы активности комплемента
|
|
GB2551945B
(en)
*
|
2015-12-18 |
2021-09-08 |
Heptares Therapeutics Ltd |
Novel GLP-1 receptor agonist peptides
|
|
WO2017149070A1
(en)
|
2016-03-03 |
2017-09-08 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
MA53353A
(fr)
|
2016-05-16 |
2021-06-09 |
Intarcia Therapeutics Inc |
Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
CN107561168A
(zh)
*
|
2016-06-30 |
2018-01-09 |
山东新时代药业有限公司 |
一种聚乙二醇化促胰岛素分泌肽类似物的分析检测方法
|
|
MA46780A
(fr)
|
2016-11-07 |
2019-09-11 |
Novo Nordisk As |
Esters à dchbs actif de composés peg et leur utilisation
|
|
WO2018106643A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic azoles for the treatment of demyelinating diseases
|
|
WO2018106641A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Pyrazoles for the treatment of demyelinating diseases
|
|
WO2018106646A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Aminotriazoles for the treatment of demyelinating diseases
|
|
MX2019006527A
(es)
|
2016-12-07 |
2019-08-01 |
Ra Pharmaceuticals Inc |
Moduladores de la actividad del complemento.
|
|
KR20190104039A
(ko)
|
2017-01-03 |
2019-09-05 |
인타르시아 세라퓨틱스 인코포레이티드 |
Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
|
|
ES2875562T3
(es)
|
2017-01-11 |
2021-11-10 |
Alkermes Inc |
Inhibidores bicíclicos de histona desacetilasa
|
|
FR3061715B1
(fr)
|
2017-01-12 |
2021-07-30 |
Institut National Univ Jean Francois Champollion |
Peptide immunomodulateur
|
|
US20200188479A1
(en)
*
|
2017-03-08 |
2020-06-18 |
Intarcia Therapeutics, Inc. |
Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
|
|
TWI797133B
(zh)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於經口投予的固體組成物
|
|
US11225475B2
(en)
|
2017-08-07 |
2022-01-18 |
Alkermes, Inc. |
Substituted pyridines as inhibitors of histone deacetylase
|
|
EP3474820B1
(en)
|
2017-08-24 |
2024-02-07 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
|
SG11202002259XA
(en)
*
|
2017-09-19 |
2020-04-29 |
Immunwork Inc |
Pharmaceutical constructs with enhanced binding affinity with albumin
|
|
KR20200069316A
(ko)
|
2017-10-12 |
2020-06-16 |
노보 노르디스크 에이/에스 |
의료 요법에서의 세마글루타이드
|
|
BR112020014624A2
(pt)
|
2018-02-02 |
2020-12-08 |
Novo Nordisk A/S |
Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
|
|
PE20211417A1
(es)
|
2018-04-05 |
2021-08-02 |
Sun Pharmaceutical Ind Ltd |
Analogos novedosos de glp-1
|
|
CN112074531B
(zh)
|
2018-05-04 |
2025-04-15 |
诺和诺德股份有限公司 |
Gip衍生物及其用途
|
|
TWI829687B
(zh)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|
|
CN109111361A
(zh)
*
|
2018-10-08 |
2019-01-01 |
扬州工业职业技术学院 |
一种一步法高效制备十二烷基二酸单叔丁酯的方法
|
|
CN109134257A
(zh)
*
|
2018-10-08 |
2019-01-04 |
扬州工业职业技术学院 |
一种两步法制备高纯度十二烷基二酸单叔丁酯的方法
|
|
WO2020118843A1
(zh)
*
|
2018-12-12 |
2020-06-18 |
四川利通科创生物医药科技有限公司 |
一种glp-1突变体及其制备方法和用途
|
|
CN113329810A
(zh)
|
2019-01-24 |
2021-08-31 |
诺和诺德股份有限公司 |
辊压机和使用辊压机的干法制粒方法
|
|
EP3930757A1
(en)
|
2019-03-01 |
2022-01-05 |
President And Fellows Of Harvard College |
Methods and compositions for protein delivery
|
|
WO2020205409A1
(en)
|
2019-04-03 |
2020-10-08 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
|
WO2021070202A1
(en)
*
|
2019-10-09 |
2021-04-15 |
Prasad Alaparthi Lakshmi |
A method for preparing glp-1 analogue by solid-phase peptide synthesis
|
|
RS65780B1
(sr)
|
2019-11-06 |
2024-08-30 |
Novo Nordisk As |
Semaglutid u lečenju alchajmerove demencije
|
|
CN114641276A
(zh)
|
2019-11-07 |
2022-06-17 |
诺和诺德股份有限公司 |
包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
|
|
JP2023503899A
(ja)
|
2019-11-22 |
2023-02-01 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
薬物送達のためのイオン液体
|
|
CN116925237A
(zh)
|
2019-12-31 |
2023-10-24 |
北京质肽生物医药科技有限公司 |
Glp-1和gdf15的融合蛋白以及其缀合物
|
|
PE20230819A1
(es)
|
2020-02-18 |
2023-05-19 |
Novo Nordisk As |
Composiciones y usos de glp-1
|
|
GB202003762D0
(en)
*
|
2020-03-16 |
2020-04-29 |
Heptares Therapeutics Ltd |
GLP receptor agonists
|
|
JP7777085B2
(ja)
|
2020-04-29 |
2025-11-27 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
|
|
TW202144393A
(zh)
*
|
2020-05-29 |
2021-12-01 |
大陸商北京拓界生物醫藥科技有限公司 |
Ｇｌｐ－１和ｇｉｐ受體雙重激動劑化合物及其應用
|
|
EP4181946A1
(en)
*
|
2020-07-18 |
2023-05-24 |
Dr. Reddy's Laboratories Ltd. |
Improved purification process of semaglutide
|
|
CN116157143A
(zh)
|
2020-07-22 |
2023-05-23 |
诺和诺德股份有限公司 |
适合于口服递送的glp-1和gip受体的共激动剂
|
|
JP2023545684A
(ja)
*
|
2020-09-30 |
2023-10-31 |
ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド |
ポリペプチドコンジュゲートおよび使用の方法
|
|
US20250268986A1
(en)
|
2020-11-06 |
2025-08-28 |
Novo Nordisk A/S |
Glp-1 prodrugs and uses thereof
|
|
TW202440619A
(zh)
*
|
2020-12-18 |
2024-10-16 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1及澱粉素受體之共促效劑
|
|
CN114685644A
(zh)
*
|
2020-12-29 |
2022-07-01 |
苏州康宁杰瑞生物科技有限公司 |
一种人glp-1多肽变体及其应用
|
|
WO2022175384A1
(en)
*
|
2021-02-17 |
2022-08-25 |
Fundación Universidad Católica De Valencia San Vicente Mártir |
Small-molecule agents with antiviral activity against rna viruses
|
|
AU2022289610A1
(en)
|
2021-06-09 |
2024-01-25 |
The Scripps Research Institute |
Long-acting dual gip/glp-1 peptide conjugates and methods of use
|
|
WO2023012263A1
(en)
|
2021-08-04 |
2023-02-09 |
Novo Nordisk A/S |
Solid oral peptide formulations
|
|
CA3233824A1
(en)
|
2021-10-08 |
2023-04-13 |
Samir Mitragotri |
Ionic liquids for drug delivery
|
|
WO2023086499A1
(en)
|
2021-11-10 |
2023-05-19 |
I2O Therapeutics, Inc. |
Ionic liquid compositions
|
|
TW202330584A
(zh)
|
2022-01-20 |
2023-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
前藥及其用途
|
|
CA3252113A1
(en)
|
2022-03-30 |
2023-10-05 |
Beijing Ql Biopharmaceutical Co Ltd |
Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use
|
|
CN119173275A
(zh)
|
2022-05-10 |
2024-12-20 |
诺和诺德股份有限公司 |
Glp-1多肽的前药及其用途
|
|
JP2025521647A
(ja)
|
2022-06-30 |
2025-07-10 |
サノフイ |
選択的ｉｌ－２３受容体アンタゴニストとしての新規ペプチド
|
|
CN115785249B
(zh)
*
|
2022-10-13 |
2023-07-21 |
江苏师范大学 |
一类glp-1类似物及其应用
|
|
WO2024110614A1
(en)
|
2022-11-25 |
2024-05-30 |
Novo Nordisk A/S |
Oral administration of peptide therapeutics, such as glp-1
|
|
EP4642440A1
(en)
|
2022-12-30 |
2025-11-05 |
Algipharma As |
Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
|
|
WO2024245946A1
(en)
*
|
2023-05-26 |
2024-12-05 |
Gubra A/S |
Secretin-derived glp1r selective agonists
|
|
WO2025098422A1
(zh)
*
|
2023-11-07 |
2025-05-15 |
深圳信立泰药业股份有限公司 |
多重受体共激动剂化合物及其制备方法与应用
|